Revenue Update on Exactech(NASDAQ:EXAC)

Exactech(NASDAQ:EXAC) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 1, 2016. Company reported revenue of $66.12M. Analysts estimated a revenue of $64.18M. Earnings per share were $0.31. Analysts had estimated an EPS of $0.30.

Exactech (EXAC) made into the market gainers list on Mondays trading session with the shares advancing 0.14% or 0.04 points. Due to strong positive momentum, the stock ended at $28.32, which is also near the day’s high of $28.66. The stock began the session at $28.37 and the volume stood at 33,021 shares. The 52-week high of the shares is $28.66 and the 52 week low is $16.11. The company has a current market capitalization of $399 M and it has 1,40,96,402 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jul 5, 2016, Joel C Phillips (EVP/CFO/Treasurer) sold 3,000 shares at $26.75 per share price.Also, On Jun 9, 2016, Gary J Miller (Executive Vice President, R&D) sold 9,800 shares at $25.13 per share price.On Jun 9, 2016, Bruce E Thompson (Sr VP, Biologics & Spine) sold 2,000 shares at $25.07 per share price, according to the Form-4 filing with the securities and exchange commission.

Exactech Inc. develops manufactures markets distributes and sells orthopedic implant devices related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally. The Company’s operating segments are represented by its major product lines: knee implants hip implants biologics and spine extremity implants and other products. Its other products segment includes miscellaneous sales categories such as surgical instruments held for sale bone cement instrument rental fees shipping charges and other implant product lines. The Company manufactures some components of its knee extremity and hip joint replacement systems at its facility in Gainesville Florida. Its joint replacement products are used by orthopedic surgeons to repair or replace joints that have deteriorated as a result of injury or disease. Its spinal implants are used as an adjunct to the fusion of vertebrae in the treatment of spinal disease and deformity.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Exactech - Is it time to Sell?

Top Brokerage Firms are advising their investors on Exactech. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.